Hansoh Pharma Strategically Invests in Carbon Intelligence Peptide to Advance AI-Driven Peptide Drug Development and Industrial Collaboration

Gelonghui December 22 | According to Hybio Pharmaceutical, recently, Hybio Pharmaceutical Co., Ltd. officially reached a strategic investment cooperation with iCarbonX All. According to the agreement, Hybio Pharmaceutical will subscribe for the new registered capital of iCarbonX All with 10 million yuan in cash. After the completion of the capital increase, it will hold 0.6623% of its equity, marking that both parties have moved from the preliminary R&D collaboration to the deep cooperation stage of capital binding and industrial synergy.